首页 > 最新文献

Lancet Neurology最新文献

英文 中文
Reassessing the implications of atrial fibrillation detected after stroke. 重新评估中风后检测到的心房颤动的影响。
IF 46.5 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2023-10-12 DOI: 10.1016/S1474-4422(23)00406-4
Hooman Kamel
{"title":"Reassessing the implications of atrial fibrillation detected after stroke.","authors":"Hooman Kamel","doi":"10.1016/S1474-4422(23)00406-4","DOIUrl":"10.1016/S1474-4422(23)00406-4","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"9-11"},"PeriodicalIF":46.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41236520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack. 对中风或短暂性脑缺血发作后检测到的心房颤动进行新的分类。
IF 46.5 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2023-10-12 DOI: 10.1016/S1474-4422(23)00326-5
Luciano A Sposato, Thalia S Field, Renate B Schnabel, Rolf Wachter, Jason G Andrade, Michael D Hill

Globally, up to 1·5 million individuals with ischaemic stroke or transient ischaemic attack can be newly diagnosed with atrial fibrillation per year. In the past decade, evidence has accumulated supporting the notion that atrial fibrillation first detected after a stroke or transient ischaemic attack differs from atrial fibrillation known before the occurrence of as stroke. Atrial fibrillation detected after stroke is associated with a lower prevalence of risk factors, cardiovascular comorbidities, and atrial cardiomyopathy than atrial fibrillation known before stroke occurrence. These differences might explain why it is associated with a lower risk of recurrence of ischaemic stroke than known atrial fibrillation. Patients with ischaemic stroke or transient ischaemic attack can be classified in three categories: no atrial fibrillation, known atrial fibrillation before stroke occurrence, and atrial fibrillation detected after stroke. This classification could harmonise future research in the field and help to understand the role of prolonged cardiac monitoring for secondary stroke prevention with application of a personalised risk-based approach to the selection of patients for anticoagulation.

在全球范围内,每年有多达150万缺血性中风或短暂性缺血性发作患者被新诊断为心房颤动。在过去的十年里,积累的证据支持这样一种观点,即在中风或短暂性缺血性发作后首次检测到的心房颤动与中风发生前已知的心房颤动不同。与中风发生前已知的心房颤动相比,中风后检测到的心房颤动与风险因素、心血管合并症和心房心肌病的患病率较低有关。这些差异可能解释了为什么与已知的心房颤动相比,它与缺血性中风复发的风险更低有关。缺血性卒中或短暂性缺血性发作的患者可分为三类:无心房颤动、卒中发生前已知的心房颤动和卒中后检测到的心房颤动。这一分类可以协调该领域未来的研究,并有助于了解长期心脏监测在二次中风预防中的作用,以及在选择抗凝患者时应用个性化的基于风险的方法。
{"title":"Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.","authors":"Luciano A Sposato, Thalia S Field, Renate B Schnabel, Rolf Wachter, Jason G Andrade, Michael D Hill","doi":"10.1016/S1474-4422(23)00326-5","DOIUrl":"10.1016/S1474-4422(23)00326-5","url":null,"abstract":"<p><p>Globally, up to 1·5 million individuals with ischaemic stroke or transient ischaemic attack can be newly diagnosed with atrial fibrillation per year. In the past decade, evidence has accumulated supporting the notion that atrial fibrillation first detected after a stroke or transient ischaemic attack differs from atrial fibrillation known before the occurrence of as stroke. Atrial fibrillation detected after stroke is associated with a lower prevalence of risk factors, cardiovascular comorbidities, and atrial cardiomyopathy than atrial fibrillation known before stroke occurrence. These differences might explain why it is associated with a lower risk of recurrence of ischaemic stroke than known atrial fibrillation. Patients with ischaemic stroke or transient ischaemic attack can be classified in three categories: no atrial fibrillation, known atrial fibrillation before stroke occurrence, and atrial fibrillation detected after stroke. This classification could harmonise future research in the field and help to understand the role of prolonged cardiac monitoring for secondary stroke prevention with application of a personalised risk-based approach to the selection of patients for anticoagulation.</p>","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"110-122"},"PeriodicalIF":46.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41236585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. 自发性颅内出血后心房颤动患者口服抗凝治疗的效果:随机试验的前瞻性个体参与者数据荟萃分析。
IF 48 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-12 DOI: 10.1016/S1474-4422(23)00315-0
Rustam Al-Shahi Salman, Jacqueline Stephen, Jayne F Tierney, Steff C Lewis, David E Newby, Adrian R Parry-Jones, Philip M White, Stuart J Connolly, Oscar R Benavente, Dar Dowlatshahi, Charlotte Cordonnier, Catherine M Viscoli, Kevin N Sheth, Hooman Kamel, Roland Veltkamp, Kristin T Larsen, Jeannette Hofmeijer, Henk Kerkhoff, Floris H B M Schreuder, Ashkan Shoamanesh, Catharina J M Klijn, H Bart van der Worp
<p><strong>Background: </strong>The safety and efficacy of oral anticoagulation for prevention of major adverse cardiovascular events in people with atrial fibrillation and spontaneous intracranial haemorrhage are uncertain. We planned to estimate the effects of starting versus avoiding oral anticoagulation in people with spontaneous intracranial haemorrhage and atrial fibrillation.</p><p><strong>Methods: </strong>In this prospective meta-analysis, we searched bibliographic databases and trial registries using the strategies of a Cochrane systematic review (CD012144) on June 23, 2023. We included clinical trials if they were registered, randomised, and included participants with spontaneous intracranial haemorrhage and atrial fibrillation who were assigned to either start long-term use of any oral anticoagulant agent or avoid oral anticoagulation (ie, placebo, open control, another antithrombotic agent, or another intervention for the prevention of major adverse cardiovascular events). We assessed eligible trials using the Cochrane Risk of Bias tool. We sought data for individual participants who had not opted out of data sharing from chief investigators of completed trials, pending completion of ongoing trials in 2028. The primary outcome was any stroke or cardiovascular death. We used individual participant data to construct a Cox regression model of the time to the first occurrence of outcome events during follow-up in the intention-to-treat dataset supplied by each trial, followed by meta-analysis using a fixed-effect inverse-variance model to generate a pooled estimate of the hazard ratio (HR) with 95% CI. This study is registered with PROSPERO, CRD42021246133.</p><p><strong>Findings: </strong>We identified four eligible trials; three were restricted to participants with atrial fibrillation and intracranial haemorrhage (SoSTART [NCT03153150], with 203 participants) or intracerebral haemorrhage (APACHE-AF [NCT02565693], with 101 participants, and NASPAF-ICH [NCT02998905], with 30 participants), and one included a subgroup of participants with previous intracranial haemorrhage (ELDERCARE-AF [NCT02801669], with 80 participants). After excluding two participants who opted out of data sharing, we included 412 participants (310 [75%] aged 75 years or older, 249 [60%] with CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≤4, and 163 [40%] with CHA<sub>2</sub>DS<sub>2</sub>-VASc score >4). The intervention was a direct oral anticoagulant in 209 (99%) of 212 participants who were assigned to start oral anticoagulation, and the comparator was antiplatelet monotherapy in 67 (33%) of 200 participants assigned to avoid oral anticoagulation. The primary outcome of any stroke or cardiovascular death occurred in 29 (14%) of 212 participants who started oral anticoagulation versus 43 (22%) of 200 who avoided oral anticoagulation (pooled HR 0·68 [95% CI 0·42-1·10]; I<sup>2</sup>=0%). Oral anticoagulation reduced the risk of ischaemic major adverse cardiovascular even
背景:口服抗凝药物预防心房颤动和自发性颅内出血患者主要心血管不良事件的安全性和有效性尚不确定。我们计划评估在自发性颅内出血和心房颤动患者中开始和避免口服抗凝的效果。方法:在这项前瞻性荟萃分析中,我们在2023年6月23日使用Cochrane系统综述(CD012144)的策略搜索了文献数据库和试验登记处。如果临床试验是注册的、随机的,包括自发性颅内出血和心房颤动的参与者,他们被分配开始长期使用任何口服抗凝剂或避免口服抗凝剂(即安慰剂、开放对照、另一种抗凝血剂或预防重大心血管不良事件的另一种干预措施)。我们使用Cochrane偏倚风险工具评估了符合条件的试验。在2028年正在进行的试验完成之前,我们向已完成试验的首席研究员寻求未选择退出数据共享的个体参与者的数据。主要结果是任何中风或心血管死亡。我们使用个体参与者的数据,在每次试验提供的意向治疗数据集中,构建了随访期间结果事件首次发生的时间的Cox回归模型,然后使用固定效应逆方差模型进行荟萃分析,以产生95%CI的风险比(HR)的汇总估计。该研究在PROSPERO注册,CRD42021246133.研究结果:我们确定了四项符合条件的试验;三个仅限于患有心房颤动和颅内出血(SoSTART[NCT0313150],203名参与者)或脑出血(APACHE-AF[NCT0255693],101名参与者,NASPAF-ICH[NCT0298905],30名参与者)的参与者,其中一个包括既往有颅内出血的参与者亚组(ELDERCARE-AF[NCT02801669],有80名参与者)。在排除两名选择退出数据共享的参与者后,我们纳入了412名参与者(310[75%],年龄在75岁或以上,249[60%],CHA2DS2 VASc评分≤4,163[40%],CHA2DS2 VASc评分>4)。在212名被分配开始口服抗凝的参与者中,209人(99%)接受了直接口服抗凝剂干预,200名被分配避免口服抗凝剂的参与者中有67人(33%)接受了抗血小板单药治疗。212名开始口服抗凝治疗的参与者中有29人(14%)出现了任何中风或心血管死亡的主要结果,而200名避免口服抗凝的参与者中则有43人(22%)出现了这些结果(合并HR 0.68[95%CI 0.42-1.10];I2=0%)。口服抗凝降低了缺血性主要心血管不良事件的风险(212例中有9例[4%],200例中有38例[19%];合并HR 0.27[95%CI 0.13-0.56];I2=0%)。出血性主要心血管不良事件没有显著增加(212例中有15例[7%]对200例中有9例[5%];合并HR为1.80[95%CI为0.77-4.21];I2=0%),任何原因的死亡(212例的38例[18%对200例的29例[15%];1.78-2.11];I2=50%),或1年后死亡或依赖(147例中的78例[53%]vs 145例中的74例[51%];合并优势比为1.12[95%CI 0.70-1.79];I2=0%)。解释:对于心房颤动和颅内出血患者,口服抗凝对任何中风或心血管死亡(总体和亚组)、出血性主要心血管不良事件、,以及功能结果。口服抗凝降低了缺血性主要心血管不良事件的风险,这可以为临床实践提供信息。这些发现应鼓励招募人员参加并完成正在进行的试验。资助:英国心脏基金会。
{"title":"Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.","authors":"Rustam Al-Shahi Salman, Jacqueline Stephen, Jayne F Tierney, Steff C Lewis, David E Newby, Adrian R Parry-Jones, Philip M White, Stuart J Connolly, Oscar R Benavente, Dar Dowlatshahi, Charlotte Cordonnier, Catherine M Viscoli, Kevin N Sheth, Hooman Kamel, Roland Veltkamp, Kristin T Larsen, Jeannette Hofmeijer, Henk Kerkhoff, Floris H B M Schreuder, Ashkan Shoamanesh, Catharina J M Klijn, H Bart van der Worp","doi":"10.1016/S1474-4422(23)00315-0","DOIUrl":"10.1016/S1474-4422(23)00315-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The safety and efficacy of oral anticoagulation for prevention of major adverse cardiovascular events in people with atrial fibrillation and spontaneous intracranial haemorrhage are uncertain. We planned to estimate the effects of starting versus avoiding oral anticoagulation in people with spontaneous intracranial haemorrhage and atrial fibrillation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this prospective meta-analysis, we searched bibliographic databases and trial registries using the strategies of a Cochrane systematic review (CD012144) on June 23, 2023. We included clinical trials if they were registered, randomised, and included participants with spontaneous intracranial haemorrhage and atrial fibrillation who were assigned to either start long-term use of any oral anticoagulant agent or avoid oral anticoagulation (ie, placebo, open control, another antithrombotic agent, or another intervention for the prevention of major adverse cardiovascular events). We assessed eligible trials using the Cochrane Risk of Bias tool. We sought data for individual participants who had not opted out of data sharing from chief investigators of completed trials, pending completion of ongoing trials in 2028. The primary outcome was any stroke or cardiovascular death. We used individual participant data to construct a Cox regression model of the time to the first occurrence of outcome events during follow-up in the intention-to-treat dataset supplied by each trial, followed by meta-analysis using a fixed-effect inverse-variance model to generate a pooled estimate of the hazard ratio (HR) with 95% CI. This study is registered with PROSPERO, CRD42021246133.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;We identified four eligible trials; three were restricted to participants with atrial fibrillation and intracranial haemorrhage (SoSTART [NCT03153150], with 203 participants) or intracerebral haemorrhage (APACHE-AF [NCT02565693], with 101 participants, and NASPAF-ICH [NCT02998905], with 30 participants), and one included a subgroup of participants with previous intracranial haemorrhage (ELDERCARE-AF [NCT02801669], with 80 participants). After excluding two participants who opted out of data sharing, we included 412 participants (310 [75%] aged 75 years or older, 249 [60%] with CHA&lt;sub&gt;2&lt;/sub&gt;DS&lt;sub&gt;2&lt;/sub&gt;-VASc score ≤4, and 163 [40%] with CHA&lt;sub&gt;2&lt;/sub&gt;DS&lt;sub&gt;2&lt;/sub&gt;-VASc score &gt;4). The intervention was a direct oral anticoagulant in 209 (99%) of 212 participants who were assigned to start oral anticoagulation, and the comparator was antiplatelet monotherapy in 67 (33%) of 200 participants assigned to avoid oral anticoagulation. The primary outcome of any stroke or cardiovascular death occurred in 29 (14%) of 212 participants who started oral anticoagulation versus 43 (22%) of 200 who avoided oral anticoagulation (pooled HR 0·68 [95% CI 0·42-1·10]; I&lt;sup&gt;2&lt;/sup&gt;=0%). Oral anticoagulation reduced the risk of ischaemic major adverse cardiovascular even","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1140-1149"},"PeriodicalIF":48.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41236517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Policy priorities for preventing stroke-related mortality and disability worldwide. 全世界预防中风相关死亡率和残疾的政策重点。
IF 48 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-09 DOI: 10.1016/S1474-4422(23)00387-3
David A Watkins
{"title":"Policy priorities for preventing stroke-related mortality and disability worldwide.","authors":"David A Watkins","doi":"10.1016/S1474-4422(23)00387-3","DOIUrl":"10.1016/S1474-4422(23)00387-3","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1096-1098"},"PeriodicalIF":48.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41204409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission. 减少全球中风负担的务实解决方案:世界中风组织柳叶刀神经病学委员会。
IF 46.5 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-09 DOI: 10.1016/S1474-4422(23)00277-6
Valery L Feigin, Mayowa O Owolabi
{"title":"Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.","authors":"Valery L Feigin, Mayowa O Owolabi","doi":"10.1016/S1474-4422(23)00277-6","DOIUrl":"10.1016/S1474-4422(23)00277-6","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1160-1206"},"PeriodicalIF":46.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41204410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital mobility measures to predict Parkinson's disease. 预测帕金森病的数字移动测量。
IF 48 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-18 DOI: 10.1016/S1474-4422(23)00376-9
Anat Mirelman, Lynn Rochester, Tanya Simuni, Jeffrey M Hausdoff
{"title":"Digital mobility measures to predict Parkinson's disease.","authors":"Anat Mirelman, Lynn Rochester, Tanya Simuni, Jeffrey M Hausdoff","doi":"10.1016/S1474-4422(23)00376-9","DOIUrl":"10.1016/S1474-4422(23)00376-9","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1098-1100"},"PeriodicalIF":48.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49679061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease. 平衡逆境的规模:减少中风和心血管疾病全球负担的社会生态学方法。
IF 48 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-09 DOI: 10.1016/S1474-4422(23)00386-1
Samuel B Brusca, Michelle A Albert
{"title":"Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.","authors":"Samuel B Brusca, Michelle A Albert","doi":"10.1016/S1474-4422(23)00386-1","DOIUrl":"10.1016/S1474-4422(23)00386-1","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1094-1096"},"PeriodicalIF":48.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41204408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Neurol 2023; 22: 812-25. 《柳叶刀神经杂志》更正2023;22:812-25。
IF 48 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-17 DOI: 10.1016/S1474-4422(23)00411-8
{"title":"Correction to Lancet Neurol 2023; 22: 812-25.","authors":"","doi":"10.1016/S1474-4422(23)00411-8","DOIUrl":"10.1016/S1474-4422(23)00411-8","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"e13"},"PeriodicalIF":48.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49679060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage. 颅内出血后心房颤动患者的抗凝治疗。
IF 48 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-12-01 Epub Date: 2023-10-12 DOI: 10.1016/S1474-4422(23)00331-9
Shinichiro Uchiyama
{"title":"Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.","authors":"Shinichiro Uchiyama","doi":"10.1016/S1474-4422(23)00331-9","DOIUrl":"10.1016/S1474-4422(23)00331-9","url":null,"abstract":"","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1091-1092"},"PeriodicalIF":48.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41236516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. 在非洲和非洲混合人群中识别与帕金森病相关的遗传风险基因座和因果见解:一项全基因组关联研究。
IF 46.5 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2023-11-01 Epub Date: 2023-08-23 DOI: 10.1016/S1474-4422(23)00283-1
Mie Rizig, Sara Bandres-Ciga, Mary B Makarious, Oluwadamilola Omolara Ojo, Peter Wild Crea, Oladunni Victoria Abiodun, Kristin S Levine, Sani Atta Abubakar, Charles Obiora Achoru, Dan Vitale, Olaleye Akinmola Adeniji, Osigwe Paul Agabi, Mathew J Koretsky, Uchechi Agulanna, Deborah A Hall, Rufus Olusola Akinyemi, Tao Xie, Mohammed Wulgo Ali, Ejaz A Shamim, Ifeyinwa Ani-Osheku, Mahesh Padmanaban, Ohwotemu Michael Arigbodi, David G Standaert, Abiodun Hamzat Bello, Marissa N Dean, Cyril Oshomah Erameh, Inas Elsayed, Temitope Hannah Farombi, Olaitan Okunoye, Michael Bimbola Fawale, Kimberley J Billingsley, Frank Aiwansoba Imarhiagbe, Pilar Alvarez Jerez, Emmanuel Uzodinma Iwuozo, Breeana Baker, Morenikeji Adeyoyin Komolafe, Laksh Malik, Paul Osemeke Nwani, Kensuke Daida, Ernest Okwundu Nwazor, Abigail Miano-Burkhardt, Yakub Wilberforce Nyandaiti, Zih-Hua Fang, Yahaya Olugbo Obiabo, Jillian H Kluss, Olanike Adedoyin Odeniyi, Dena G Hernandez, Francis Ehidiamen Odiase, Nahid Tayebi, Francis Ibe Ojini, Ellen Sidranksy, Gerald Awele Onwuegbuzie, Andrea M D'Souza, Godwin Osawaru Osaigbovo, Bahafta Berhe, Nosakhare Osemwegie, Xylena Reed, Olajumoke Olufemi Oshinaike, Hampton L Leonard, Folajimi Morenikeji Otubogun, Chelsea X Alvarado, Shyngle Imiewan Oyakhire, Simon Izuchukwu Ozomma, Sarah Chabiri Samuel, Funmilola Tolulope Taiwo, Kolawole Wasiu Wahab, Yusuf Agboola Zubair, Hirotaka Iwaki, Jonggeol Jeffrey Kim, Huw R Morris, John Hardy, Mike A Nalls, Karl Heilbron, Lucy Norcliffe-Kaufmann, Cornelis Blauwendraat, Henry Houlden, Andrew Singleton, Njideka Ulunma Okubadejo
<p><strong>Background: </strong>An understanding of the genetic mechanisms underlying diseases in ancestrally diverse populations is an important step towards development of targeted treatments. Research in African and African admixed populations can enable mapping of complex traits, because of their genetic diversity, extensive population substructure, and distinct linkage disequilibrium patterns. We aimed to do a comprehensive genome-wide assessment in African and African admixed individuals to better understand the genetic architecture of Parkinson's disease in these underserved populations.</p><p><strong>Methods: </strong>We performed a genome-wide association study (GWAS) in people of African and African admixed ancestry with and without Parkinson's disease. Individuals were included from several cohorts that were available as a part of the Global Parkinson's Genetics Program, the International Parkinson's Disease Genomics Consortium Africa, and 23andMe. A diagnosis of Parkinson's disease was confirmed clinically by a movement disorder specialist for every individual in each cohort, except for 23andMe, in which it was self-reported based on clinical diagnosis. We characterised ancestry-specific risk, differential haplotype structure and admixture, coding and structural genetic variation, and enzymatic activity.</p><p><strong>Findings: </strong>We included 197 918 individuals (1488 cases and 196 430 controls) in our genome-wide analysis. We identified a novel common risk factor for Parkinson's disease (overall meta-analysis odds ratio for risk of Parkinson's disease 1·58 [95% CI 1·37-1·80], p=2·397 × 10<sup>-14</sup>) and age at onset at the GBA1 locus, rs3115534-G (age at onset β=-2·00 [SE=0·57], p=0·0005, for African ancestry; and β=-4·15 [0·58], p=0·015, for African admixed ancestry), which was rare in non-African or non-African admixed populations. Downstream short-read and long-read whole-genome sequencing analyses did not reveal any coding or structural variant underlying the GWAS signal. The identified signal seems to be associated with decreased glucocerebrosidase activity.</p><p><strong>Interpretation: </strong>Our study identified a novel genetic risk factor in GBA1 in people of African ancestry, which has not been seen in European populations, and it could be a major mechanistic basis of Parkinson's disease in African populations. This population-specific variant exerts substantial risk on Parkinson's disease as compared with common variation identified through GWAS and it was found to be present in 39% of the cases assessed in this study. This finding highlights the importance of understanding ancestry-specific genetic risk in complex diseases, a particularly crucial point as the Parkinson's disease field moves towards targeted treatments in clinical trials. The distinctive genetics of African populations highlights the need for equitable inclusion of ancestrally diverse groups in future trials, which will be a valuable step towar
背景:了解不同祖先人群疾病的遗传机制是开发靶向治疗方法的重要一步。对非洲和非洲混合种群的研究可以绘制复杂性状的图谱,因为它们的遗传多样性、广泛的种群亚结构和明显的连锁不平衡模式。我们的目标是对非洲和非洲混血个体进行全面的全基因组评估,以更好地了解这些服务不足人群中帕金森病的遗传结构。方法:我们对患有和不患有帕金森氏症的非洲和非洲混合血统的人进行了全基因组关联研究(GWAS)。作为全球帕金森氏遗传学计划、非洲国际帕金森氏病基因组学联合会和23andMe的一部分,来自几个队列的个体被纳入其中。运动障碍专家对每个队列中的每个人都进行了临床确认,但23andMe除外,23andMe是根据临床诊断自我报告的。我们描述了祖先特异性风险、差异单倍型结构和混合、编码和结构遗传变异以及酶活性。调查结果:我们包括197 918人(1488例和196例 430个对照)。我们确定了一种新的帕金森病常见风险因素(帕金森病风险的总体荟萃分析优势比1.58[95%CI 1.37-1.80],p=2.397 × 10-14)和GBA1基因座的发病年龄rs3115534-G(对于非洲血统,发病年龄β=-2.00[SE=0.57],p=0.0005;对于非洲混血血统,β=-4.15[0.58],p=0.015),这在非非洲或非非洲混血人群中很罕见。下游的短读和长读全基因组测序分析没有揭示GWAS信号背后的任何编码或结构变体。所识别的信号似乎与葡糖脑苷酶活性降低有关。解释:我们的研究在非洲血统的人中发现了一种新的GBA1遗传风险因素,这在欧洲人群中尚未发现,这可能是非洲人群中帕金森病的主要机制基础。与通过GWAS确定的常见变异相比,这种人群特异性变异对帕金森病具有很大的风险,并且在本研究评估的39%的病例中发现了这种变异。这一发现突显了了解复杂疾病中特定祖先遗传风险的重要性,这是帕金森病领域在临床试验中走向靶向治疗的一个特别关键的点。非洲人群独特的遗传学突出表明,在未来的试验中,需要公平地纳入具有不同祖先的群体,这将是深入了解帕金森病病因的新遗传决定因素的宝贵一步。这一发现为基于RNA和其他旨在降低帕金森病终身风险的治疗策略开辟了新的途径。资助:全球帕金森氏遗传学项目,由“跨帕金森氏症科学协调”倡议和迈克尔·J·福克斯帕金森氏症研究基金会资助。
{"title":"Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.","authors":"Mie Rizig, Sara Bandres-Ciga, Mary B Makarious, Oluwadamilola Omolara Ojo, Peter Wild Crea, Oladunni Victoria Abiodun, Kristin S Levine, Sani Atta Abubakar, Charles Obiora Achoru, Dan Vitale, Olaleye Akinmola Adeniji, Osigwe Paul Agabi, Mathew J Koretsky, Uchechi Agulanna, Deborah A Hall, Rufus Olusola Akinyemi, Tao Xie, Mohammed Wulgo Ali, Ejaz A Shamim, Ifeyinwa Ani-Osheku, Mahesh Padmanaban, Ohwotemu Michael Arigbodi, David G Standaert, Abiodun Hamzat Bello, Marissa N Dean, Cyril Oshomah Erameh, Inas Elsayed, Temitope Hannah Farombi, Olaitan Okunoye, Michael Bimbola Fawale, Kimberley J Billingsley, Frank Aiwansoba Imarhiagbe, Pilar Alvarez Jerez, Emmanuel Uzodinma Iwuozo, Breeana Baker, Morenikeji Adeyoyin Komolafe, Laksh Malik, Paul Osemeke Nwani, Kensuke Daida, Ernest Okwundu Nwazor, Abigail Miano-Burkhardt, Yakub Wilberforce Nyandaiti, Zih-Hua Fang, Yahaya Olugbo Obiabo, Jillian H Kluss, Olanike Adedoyin Odeniyi, Dena G Hernandez, Francis Ehidiamen Odiase, Nahid Tayebi, Francis Ibe Ojini, Ellen Sidranksy, Gerald Awele Onwuegbuzie, Andrea M D'Souza, Godwin Osawaru Osaigbovo, Bahafta Berhe, Nosakhare Osemwegie, Xylena Reed, Olajumoke Olufemi Oshinaike, Hampton L Leonard, Folajimi Morenikeji Otubogun, Chelsea X Alvarado, Shyngle Imiewan Oyakhire, Simon Izuchukwu Ozomma, Sarah Chabiri Samuel, Funmilola Tolulope Taiwo, Kolawole Wasiu Wahab, Yusuf Agboola Zubair, Hirotaka Iwaki, Jonggeol Jeffrey Kim, Huw R Morris, John Hardy, Mike A Nalls, Karl Heilbron, Lucy Norcliffe-Kaufmann, Cornelis Blauwendraat, Henry Houlden, Andrew Singleton, Njideka Ulunma Okubadejo","doi":"10.1016/S1474-4422(23)00283-1","DOIUrl":"10.1016/S1474-4422(23)00283-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;An understanding of the genetic mechanisms underlying diseases in ancestrally diverse populations is an important step towards development of targeted treatments. Research in African and African admixed populations can enable mapping of complex traits, because of their genetic diversity, extensive population substructure, and distinct linkage disequilibrium patterns. We aimed to do a comprehensive genome-wide assessment in African and African admixed individuals to better understand the genetic architecture of Parkinson's disease in these underserved populations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We performed a genome-wide association study (GWAS) in people of African and African admixed ancestry with and without Parkinson's disease. Individuals were included from several cohorts that were available as a part of the Global Parkinson's Genetics Program, the International Parkinson's Disease Genomics Consortium Africa, and 23andMe. A diagnosis of Parkinson's disease was confirmed clinically by a movement disorder specialist for every individual in each cohort, except for 23andMe, in which it was self-reported based on clinical diagnosis. We characterised ancestry-specific risk, differential haplotype structure and admixture, coding and structural genetic variation, and enzymatic activity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;We included 197 918 individuals (1488 cases and 196 430 controls) in our genome-wide analysis. We identified a novel common risk factor for Parkinson's disease (overall meta-analysis odds ratio for risk of Parkinson's disease 1·58 [95% CI 1·37-1·80], p=2·397 × 10&lt;sup&gt;-14&lt;/sup&gt;) and age at onset at the GBA1 locus, rs3115534-G (age at onset β=-2·00 [SE=0·57], p=0·0005, for African ancestry; and β=-4·15 [0·58], p=0·015, for African admixed ancestry), which was rare in non-African or non-African admixed populations. Downstream short-read and long-read whole-genome sequencing analyses did not reveal any coding or structural variant underlying the GWAS signal. The identified signal seems to be associated with decreased glucocerebrosidase activity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;Our study identified a novel genetic risk factor in GBA1 in people of African ancestry, which has not been seen in European populations, and it could be a major mechanistic basis of Parkinson's disease in African populations. This population-specific variant exerts substantial risk on Parkinson's disease as compared with common variation identified through GWAS and it was found to be present in 39% of the cases assessed in this study. This finding highlights the importance of understanding ancestry-specific genetic risk in complex diseases, a particularly crucial point as the Parkinson's disease field moves towards targeted treatments in clinical trials. The distinctive genetics of African populations highlights the need for equitable inclusion of ancestrally diverse groups in future trials, which will be a valuable step towar","PeriodicalId":17989,"journal":{"name":"Lancet Neurology","volume":" ","pages":"1015-1025"},"PeriodicalIF":46.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10147325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1